Cargando…

A pre-ablative thyroid-stimulating hormone with 30–70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients

Our aim was to clarify the optimum pre-ablative thyroid-stimulating hormone (TSH) level for initial radioiodine remnant ablation (RRA) in patients with differentiated thyroid carcinoma (DTC). From December 2015 to May 2019, 689 patients undergone RRA at Nuclear Medicine Department, Second Hospital o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Juan, Yun, Canhua, Cao, Jingjia, Ding, Shouluan, Shao, Chunchun, Wang, Lina, Huang, Fengyan, Jia, Hongying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809467/ https://www.ncbi.nlm.nih.gov/pubmed/33446744 http://dx.doi.org/10.1038/s41598-020-80015-8

Ejemplares similares

Scintigraphic evaluation of salivary gland function in thyroid cancer patients after radioiodine remnant ablation
por: Krčálová, Eva, et al.
Publicado: (2020)

Assessment of Different Radioiodine Doses for Post-ablation Therapy of Thyroid Remnants: A Systematic Review
por: Ansari, Mojtaba, et al.
Publicado: (2022)

Delay of initial radioactive iodine therapy beyond 3 months has no effect on clinical responses and overall survival in patients with thyroid carcinoma: A cohort study and a meta‐analysis
por: Cheng, Fang, et al.
Publicado: (2022)

Radioiodine Remnant Ablation: A Critical Review
por: Bal, Chandra Sekhar, et al.
Publicado: (2015)

Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer
por: Ha, Seunggyun, et al.
Publicado: (2015)

Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer
por: Pitoia, Fabián, et al.
Publicado: (2012)

Radioiodine remnant ablation in stage I adult papillary thyroid carcinoma: does it improve postoperative outcome?
por: Hay, Ian D, et al.
Publicado: (2022)

Diagnosis and Treatment of Acute Pleural Effusion following Radioiodine Remnant Ablation Post Lobectomy for Thyroid Cancer
por: Qiu, Xian, et al.
Publicado: (2022)

Assessment of three different radioiodine doses for ablation therapy of thyroid remnants: Efficiency, complications and patient comfort
por: Soyluoglu, Selin, et al.
Publicado: (2023)

SAT525 Long-Term Outcomes in Stage I Thyroid Cancer Without Radioiodine Remnant Ablation
por: Mubeen, Faiza, et al.
Publicado: (2023)

Regional Variation across Canadian Centers in Radioiodine Administration for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer Diagnosed in 2000–2010
por: Rachinsky, I., et al.
Publicado: (2016)

Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer
por: Lv, Rong-Bin, et al.
Publicado: (2017)

Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi
por: Kukulska, Aleksandra, et al.
Publicado: (2010)

Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer – a prospective comparison of long-term outcomes
por: Kukulska, Aleksandra, et al.
Publicado: (2020)

Radioiodine Thyroid Ablation in Graves’ Hyperthyroidism: Merits and Pitfalls
por: Nwatsock, J. F., et al.
Publicado: (2012)

Radioiodine remnant ablation of differentiated thyroid cancer does not further increase oxidative damage to membrane lipids - early effect
por: Makarewicz, Jacek, et al.
Publicado: (2010)

Myopathy following postoperative ablative radioiodine for follicular carcinoma of the thyroid
por: Price, Hermione C, et al.
Publicado: (2009)

Radioiodine remnant ablation in low-risk differentiated thyroid cancer patients who had R0 dissection is an over treatment
por: Bal, Chandrasekhar, et al.
Publicado: (2015)

The Effectiveness of Recombinant Human Thyroid-Stimulating Hormone versus Thyroid Hormone Withdrawal Prior to Radioiodine Remnant Ablation in Thyroid Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Pak, Kyoungjune, et al.
Publicado: (2014)

Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer
por: Biondi, Bernadette, et al.
Publicado: (2009)

Lymph node metastases >5 and metastatic lymph node ratio >0.30 of differentiated thyroid cancer predict response to radioactive iodine
por: Yun, Canhua, et al.
Publicado: (2021)

Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis
por: Ahn, Jonghwa, et al.
Publicado: (2020)

Subclinical hypothyroidism diagnosed by thyrotropin-releasing hormone stimulation test in infertile women with basal thyroid-stimulating hormone levels of 2.5 to 5.0 mIU/L
por: Lee, You-Jeong, et al.
Publicado: (2014)

Heath-related quality of life in thyroid cancer patients following radioiodine ablation
por: Taïeb, David, et al.
Publicado: (2011)

Pure Stage I Seminoma with an Elevated hCG of 25,265 mIU/ml: A Case Report
por: Katayama, Hiromichi, et al.
Publicado: (2016)

Strong Neck Accumulation of (131)I Is a Predictor of Incomplete Low-Dose Radioiodine Remnant Ablation Using Recombinant Human Thyroid-Stimulating Hormone
por: Enomoto, Keisuke, et al.
Publicado: (2015)

The role of Hashimoto thyroiditis in predicting radioiodine ablation efficacy and prognosis of low to intermediate risk differentiated thyroid cancer
por: Albano, Domenico, et al.
Publicado: (2021)

Analysis of Curative Effect and Influencing Factors of N1 Stage Papillary Thyroid Micro-Carcinoma and Papillary Thyroid Non-Micro Carcinoma After Initial Radioactive Iodine Ablation Therapy
por: Yun, Canhua, et al.
Publicado: (2021)

Effects of first radioiodine ablation on functions of salivary glands in patients with differentiated thyroid cancer
por: Upadhyaya, Arun, et al.
Publicado: (2017)

A post-publication analysis of the idealized upper reference value of 2.5 mIU/L for TSH: Time to support the thyroid axis with magnesium and iron especially in the setting of reproduction medicine
por: Moncayo, Roy, et al.
Publicado: (2017)

Efficacy and Affecting Factors of (131)I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
por: Wang, Chen, et al.
Publicado: (2018)

Conservative Management of Interstitial Pregnancy With Beta-hCG of Over 39,000 mIU/mL: A Case Report
por: Mayuga, Tom J, et al.
Publicado: (2022)

Impact of the reduction in TSH cutoff level to 6 mIU/L in neonatal screening for congenital hypothyroidism in Santa Catarina: final results
por: Nascimento, Marilza Leal, et al.
Publicado: (2020)

Recombinant TSH Stimulated Remnant Ablation Therapy in Thyroid Cancer: The Success Rate Depends on the Definition of Ablation Success—An Observational Study
por: van der Horst-Schrivers, Anouk N. A., et al.
Publicado: (2015)

Economic Evaluation of Recombinant Human Thyroid Stimulating Hormone Stimulation vs. Thyroid Hormone Withdrawal Prior to Radioiodine Ablation for Thyroid Cancer: The Korean Perspective
por: Sohn, Seo Young, et al.
Publicado: (2015)

Low vs. High Radioiodine Activity to Ablate the Thyroid after Thyroidectomy for Cancer: A Randomized Study
por: Mäenpää, Hanna O., et al.
Publicado: (2008)

I-131 remnant ablation after thyroidectomy induced hepatotoxicity in a case of thyroid cancer
por: Lin, Rong, et al.
Publicado: (2015)

MON-LB87 Recombinant Human TSH vs Thyroid Hormone Withdrawal Preparation for Radioiodine Ablation in Pediatric Differentiated Thyroid Cancer
por: Schumm, Max A, et al.
Publicado: (2020)

Impact of preconceptional serum thyroid stimulating hormone values ranging between 2.5 and 4.5 mIU/L on live birth rates following ovulation induction and intrauterine insemination treatment for unexplained infertility
por: Karakis, Lale Susan, et al.
Publicado: (2021)

Thyroid Receptor Antibody and the Development of Graves’ Orbitopathy: Clinical Experience of using Radioiodine Ablation in the Management of Graves’ Orbitopathy in post-iodine ablation hypothyroid patient
por: Christina, Edelyn, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e1j0potnppug3irk5huvcn5s15